Topical treatment of melasma

Indian Journal of Dermatology

Volumn 54, Issue 4, 2009, Pages 303-309

  Bandyopadhyay, Debabrata ^a  

^a R G KAR MEDICAL COLLEGE   (India)

Author keywords

Melasma; Newer agents; Topical treatment

Indexed keywords

ADAPALENE; ALOESIN; ALPHA TOCOPHERYL FERULATE; ANTICONVULSIVE AGENT; ARBUTIN; ASCORBIC ACID; AZELAIC ACID; CATECHIN; CORTICOSTEROID; ELLAGIC ACID; ESTROGEN; FLAVONOID; GALLIC ACID; GENTISIC ACID; GLABRIDIN; GLYCOLIC ACID; HYDROQUINONE; KOJIC ACID; LIQUIRITIN; MEQUINOL; N ACETYL 4 CYSTEAMINYLPHENOL; N ACETYLGLUCOSAMINE; NICOTINAMIDE; ORAL CONTRACEPTIVE AGENT; PHOTOSENSITIZING AGENT; RETINOIC ACID; RETINOID; STEROID; THIOCTIC ACID; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ACETOBACTER; AQUEOUS SOLUTION; ASPERGILLUS; BURNING SENSATION; CHLOASMA; CLINICAL TRIAL; COLLOID MILIUM; CONTACT DERMATITIS; CONTROLLED DRUG RELEASE; CYTOTOXICITY; DEGRADATION; DEPIGMENTATION; DERMIS; DESQUAMATION; DISEASE EXACERBATION; DNA SYNTHESIS INHIBITION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG STABILITY; DRUG USE; DRUG WITHDRAWAL; DRY SKIN; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME SUBSTRATE; EPIDERMIS; ERYTHEMA; FOLLOW UP; GLYCYRRHIZA; HISPANIC; HISTOPATHOLOGY; HUMAN; HYDROLYSIS; HYPERPIGMENTATION; HYPERTRICHOSIS; HYPOCHROMIA; HYPOPIGMENTATION; IN VITRO STUDY; IN VIVO STUDY; KERATINOCYTE; LASER; LENTIGO; MELANOCYTE; MELANOGENESIS; MELANOSIS; MELANOSOME; MICROFLORA; NAIL COLOR DEFECT; OCHRONOSIS; OVARY INSUFFICIENCY; PAIN; PATHOPHYSIOLOGY; PENICILLIUM; PHYSIOTHERAPY; PIGMENTATION; PREGNANCY; PRESCRIPTION; PROSTATE CANCER; PRURITUS; REVIEW; SKIN ALLERGY; SKIN ATROPHY; SKIN DEFECT; SKIN DISEASE; SKIN IRRITATION; SKIN MANIFESTATION; SKIN TINGLING; SOYBEAN; STIMULUS; SUNLIGHT; SYSTEMATIC REVIEW; TELANGIECTASIA; THYROID DISEASE; TOPICAL TREATMENT; TREATMENT RESPONSE; ULTRAVIOLET B RADIATION; ULTRAVIOLET RADIATION; UNSPECIFIED SIDE EFFECT;

EID: 71949128374     PISSN: 00195154     EISSN: 19983611     Source Type: Journal    
DOI: 10.4103/0019-5154.57602     Document Type: Review

References (55)

1. Pasricha JS, Khaitan BK, Dash S. Pigmentary disorders in India. Dermatol Clin 2007;25:343-522.
2. Vázquez M, Maldonado H, Benmamán C, Sánchez JL. Melasma in men. A clinical and histologic study. Int J Dermatol 1988;27:25-27
3. Grimes PE, Yamada N, Bhawan J. Light microscopic, immunohistochemical, and ultrastructural alteration in patients with melasma. Am J Dermatopathol 2005;27:96-101.
4. Kang WH, Yoon KH, Lee ES, Kim J, Lee KB, Yim H, et al. Melasma: Histopathological characteristics in 56 Korean patients. Br J Dermatol 2002;146:228-237
5. Nicolaidou E, Antoniou C, Katsambas AD. Origin, clinical presentations, and diagnosis of facial hypermelanosis. Dermatol Clin 2007;25:321-326
6. Katsambas A, Antoniou C. Melasma: Classification and treatment. J Eur Acad Dermatol Venereol 1995;4:217-223
7. Hann SK, Im S, Chung WS, Kim Do Y. Pigmentary disorders in the South East. Dermatol Clin 2007;25:431-438
8. Rigopoulos D, Gregoriou S, Katsambas A. Hyperpigmentation and melasma. J Cosmet Dermatol 2007;6:195-202.
9. Prignano F, Ortonne JP, Buggiani G, Lotti T. Therapeutic approaches to melasma. Dermatol Clin 2007;25:337-342
10. Jimbow K, Obata H, Pathak MA, Fitzpatrick TB. Mechanism of depigmentation by hydroquinone. J Invest Dermatol 1974;62:436-449
11. Draelos ZD. Cosmetic therapy. In Wolverton SE ed. Comprehensive Dermatologic Drug Therapy. 2nd ed. Philadelphia: Saunders; 2007. p. 761-774
12. Picardo M, Carrera M. New and experimental treatments of cloasma and other hypermelanoses. Dermatol Clin 2007;25:353-362
13. Hardwick N, Van Gelder LW, Van Der Merwe CA, Van Der Merwe MP. Exogenous ochronosis: An epidemiologic study. Br J Dermatol. 1989;120:229-238
14. Zawar VP, Mhaskar ST. Exogenous ochronosis following hydroquinone for melasma. J Cosmet Dermatol 2004;3:234-236
15. Barrientos N, Ortiz-Frutos J, Gómez E, Iglesias L. Allergic contact dermatitis from a bleaching cream. Am J Contact Dermat 2001;12:33-34
16. Levin CY, Maibach H. Exogenous ochronosis. An update on clinical features, causative agents and treatment options. Am J Clin Derm 2001;2:213-217
17. Draelos ZD. Skin lightening preparations and the hydroquinone controversy. Dermatol Ther 2007;20:308-313
18. Nguyen QH, Bui TP. Azelaic acid: Pharmacokinetic and pharmacodynamic properties and its therapeutic role in hyperpigmentary disorders and acne. Int J Dermatol 1995;34:75-84.
19. Halder RM, Richards GM. Topical agents used in the management of hyperpigmentation. Skin Therapy Lett 2004;9:1-3.
20. Lowe NJ, Rizk D, Grimes P, Billips M, Pincus S. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther 1988;20:945-959
21. Baliña LM, Graupe K. The treatment of melasma. 20% azelaic acid versus 4% hydroquinone cream. Int J Dermatol 1991;30:893-895
22. Verallo-Rowell VM, Verallo V, Graupe K, Lopez-Villafuerte L, Garcia-Lopez M. Double-blind comparison of azelaic acid and hydroquinone in the treatment of melasma. Acta Derm Venereol Suppl (Stockh) 1989;143:58-61. (Pubitemid 19172051)
23. Lynde CB, Kraft JN, Lynde CW. Topical treatments for melasma and postinflammatory hyperpigmentation. Skin Therapy Lett 2006;11:1-6.
24. Kahn V. Effect of kojic acid on the oxidation of KL-DOPA. Norepinephrine and dopamine by mushroom tyrosinase. Pigment Cell Res 1995;8:234-240
25. Lim JT. Treatment of melasma using kojic acid in a gel containing hydroquinone and glycolic acid. Dermatol Surg 1999;25:282-284
26. Garcia A, Fulton JE Jr. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg 1996;22:443-447
27. Nakagawa M, Kawai K, Kawai K. Contact allergy to kojic acid in skin care products. Contact Dermatitis 1995;32:9-13.
28. Gupta AK, Gover MD, Nouri K, Taylor S. The treatment of melasma: A review of clinical trials. J Am Acad Dermatol 2006; 55:1048-1065
29. Griffiths CE, Finkel LJ, Ditre CM, Hamilton TA, Ellis CN, Boorhees JJ. Topical tretinoin (retinoid acid) improves melasma: A vehicle-controlled, clinical trial. Br J Dermatol 1993;129:415-421
30. Kimbrough-Green CK, Griffiths CE, Finkel LJ, Hamilton TA, Bulengo-Ransby SM, Ellis CN, et al. Topical retinoid acid (tretinoin) for melasma in black patients: A vehicle-controlled clinical trial. Arch Dermatol 1994;130:727-733
31. Dogra S, Kanwar AJ, Parsad D. Adapalene in the treatment of melasma: A preliminary report. J Dermatol 2002;29:539-540
32. Kanwar AJ, Dhar S, Kaur S. Treatment of melasma with potent topical corticosteroids. Dermatology 1994;188:170.
33. Neering H. Treatment of melasma (chloasma) by local application of a steroid cream. Dermatologica 1975;151:349-353
34. Rendon M, Berneburg M, Arellano I, Picardo M. Treatment of melasma. J Am Acad Dermatol 2006; 54:S272-81.
35. Usuki A, Ohashi A, Sato H, Ochiai Y, Ichihashi M, Funasaka Y. The inhibitory effect of glycolic acid and lactic acid on melanin synthesis in melanoma cells. Exp Dermatol 2003;12:43-50.
36. Guevara IL, Pandya AG. Safety and efficacy of 4% hydroquinone combined with 10% glycolic acid, antioxidants, and sunscreen in the treatment of melasma. Int J Dermatol 2003;42:966-972
37. Jarratt M. Mequinol 2%/tretinoin 0.01% solution: An effective and safe alternative to hydroquinone 3% in the treatment of solar lentigines. Cutis 2004;74:319-322
38. Keeling J, Cardona L, Benitez A, Epstein R, Rendon M. Mequinol 2%/tretinoin 0.01% topical solution for the treatment of melasma in men: A case series and review of the literature. Cutis 2008;81:179-183
39. Colby SI, Schwartzel EH, Huber FJ, Highton A, Altman DJ, Epinette WW, et al. A promising new treatment for solar lentigines. J Drugs Dermatol 2003;2:147-152
40. Bang SH, Han SJ, Kim DH. Hydrolysis of arbutin to hydroquinone by human skin bacteria and its effect on antioxidant activity. J Cosmet Dermatol 2008;7:189-193
41. Chawla S, DeLong MA, Visscher MO, Wickett RR, Manga P, Boissy RE. Mechanism of tyrosinase inhibition by deoxyArbutin and its second-generation derivatives. Br J Dermatol 2008;159:1267-1274
42. Hamed SH, Sriwiriyanont P, DeLong MA, Visscher MO, Wickett RR, Boissy RE. Comparative efficacy and safety of deoxyarbutin, a new tyrosinase-inhibiting agent. J Cosmet Sci 2006;57:291-308.
43. Boissy RE, Visscher M, DeLong MA. DeoxyArbutin: A novel reversible tyrosinase inhibitor with effective in vivo skin lightening potency. Exp Dermatol 2005;14:601-608
44. Jimbow K. N-acetyl-4-S-cysteaminylphenol as a new type of depigmenting agent for the melanoderma of patients with melasma. Arch Dermatol 1991;127:1528-1534
45. Funasaka Y, Komoto M, Ichihashi M. Depigmenting effect of alpha-tocopheryl ferulate on normal human melanocytes. Pigment Cell Res 2000;13:170-174
46. Ichihashi M, Funasaka Y, Ohashi A, Chacraborty A, Ahmed NU, Ueda M, et al. The inhibitory effect of DL-alpha-tocopheryl ferulate in lecithin on melanogenesis. Anticancer Res 1999;19:3769-3774
47. Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A doubleblind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol 2004;43:604-607
48. Hwang SW, Oh DJ, Lee D, Kim JW, Park SW. Clinical Efficacy of 25% l-Ascorbic Acid (C.ensil) in the Treatment of Melasma. J Cutan Med Surg 2009;13:74-81.
49. Kobayashi S, Takehana M, Itoh S, Ogata E. Protective effect of magnesium-L-ascorbyl-2 phosphate against skin damage induced by UVB irradiation. Photochem Photobiol 1996;64:224-228
50. Kameyama K, Sakai C, Kondoh S, Yonemoto K, Nishiyama S, Tagawa M, et al. Inhibitory effect of magnesium L-ascorbyl-2-phosphate (VC-PMG) on melanogenesis in vitro and in vivo. J Am Acad Dermatol 1996;34:29-33.
51. Greatens A, Hakozaki T, Koshoffer A, Epstein H, Schwemberger S, Babcock G, et al. Effective inhibition of melanosome transfer to keratinocytes by lectins and niacinamide is reversible. Exp Dermatol 2005;14:498-508.
52. Hakozaki T, Minwalla L, Zhuang J, Chhoa M, Matsubara A, Miyamoto K, et al. The effect of niacinamide on reducing cutaneous pigmentation and suppression of melanosome transfer. Br J Dermatol 2002;147:20-31.
53. Yokota T, Nishio H, Kubota Y, Mizoguchi M. The inhibitory effect of glabridin from licorice extracts on melanogenesis and inflammation. Pigment Cell Res 1998;11:355-361
54. Amer M, Metwalli M. Topical liquiritin improves melasma. Int J Dermatol 2000;39:299-301.
55. Kligman AM, Willis I. A new formula for depigmenting human skin. Arch Dermatol 1975;111:40-48